CORT Price Prediction Next Week
Analysis and Insights
Technical Analysis:
CORT's stock price is currently showing bearish momentum. The Relative Strength Index (RSI) for CORT is at 27.19 (6-period), 34.34 (12-period), and 36.47 (14-period), indicating the stock is in oversold territory. The MACD is negative, and the stock is trading below its 20, 50, 60, and 200-day moving averages, suggesting a strong downtrend.
Fibonacci Levels:
The Fibonacci pivot point for CORT is at 58.61, with resistance levels at 63.27 and 66.15, and support levels at 53.94 and 51.06. The stock is currently trading near the lower support levels, indicating potential oversold conditions.
Insider and Institutional Activity:
There has been significant insider selling activity, with Joseph Douglas Lyon selling 33.7% of his holdings. Institutional investors have shown mixed sentiment, with 185 increasing their positions and 167 decreasing theirs in the last quarter.
News Sentiment:
CORT is scheduled to report earnings, which could impact the stock price. However, the overall sentiment remains cautious due to insider selling and technical indicators pointing to a downtrend.
Price Prediction:
Based on the technical indicators and insider activity, the stock is expected to test the lower Fibonacci support level of 51.06 next week. The bearish trend and oversold conditions suggest a potential price of $51.06.
Recommendation:
Sell CORT stock as the technical indicators and insider activity suggest continued downward pressure.
CORT Similar Chart Price Prediction
The price of CORT is predicted to go up -28.65%, based on the high correlation periods with PLUG. The similarity of these two price pattern on the periods is 96.46%.
CORT
PLUG
Down: -28.65%Similarity: 96.46%
CORT Revenue Forecast
CORT EPS Forecast
CORT FAQs
What is CORT revenue forecast for next quarter？
CORT Analyst's Forecast
David Amsellem
Piper Sandler
Buy
2025-02-27
Price Target
$67 → $78
Upside
+30.09%
Piper Sandler analyst David Amsellem raised the firm's price target on Corcept Therapeutics to $78 from $67 and keeps an Overweight rating on the shares following quarterly results. Looking ahead, the potential approval of relacorilant could render the current debate regarding Korlym exclusivity and exposure to generics as largely irrelevant, Piper adds.
Edward Nash
Canaccord Genuity
Strong Buy
2025-01-30
Price Target
$78 → $130
Upside
+91.09%
Joon Lee
Truist Securities
Strong Buy
2024-09-30
Price Target
$65 → $76
Upside
+64.22%
